1. Steliarova-Foucher E, Colombet M, Ries LAG, et al. IICC-3 contributors. (2017) International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol, 18(6): 719-731. [DOI:10.1016/S1470-2045(17)30186-9]

2. Zaorsky NG, Allenby T, Lin J, et al. (2021) Exercise therapy and radiation therapy for cancer: A systematic review. Int J Radiat Oncol Biol Phys, 110(4): 973-983. [DOI:10.1016/j.ijrobp.2020.11.024]

3. Wells EM and Packer RJ (2015) Pediatric brain tumors. Continuum (Minneap Minn), 21(2 Neuro-oncology): 373-96. [DOI:10.1212/01.CON.0000464176.96311.d1]

4. Perez EA, Gutierrez JC, Koniaris LG, et al. (2009) Malignant pancreatic tumors: incidence and outcome in 58 pediatric patients. J Pediatr Surg, 44(1): 197-203. [DOI:10.1016/j.jpedsurg.2008.10.039]

5. Zaorsky NG, Allenby T, Lin J, et al. (2021) Exercise Therapy and Radiation Therapy for Cancer: A systematic review. Int J Radiat Oncol Biol Phys, 110(4): 973-983. [DOI:10.1016/j.ijrobp.2020.11.024]

6. Schuchardt C, Zhang J, Kulkarni HR, et al. (2022) Prostate-Specific Membrane Antigen Radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: Comparison of safety, biodistribution, and dosimetry. J Nucl Med, 63(8): 1199-1207. [DOI:10.2967/jnumed.121.262713]

7. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P (2005) International classification of childhood cancer, third edition. Cancer, 03(7): 1457-67. [DOI:10.1002/cncr.20910]

8. Suk Y, Gwynne WD, Burns I, et al. (2022) Childhood medulloblastoma: An Overview. Methods Mol Biol, 2423: 1-12. [DOI:10.1007/978-1-0716-1952-0_1]

9. Foroudi F, Tyldesley S, Barbera L, et al. (2003) Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer. Int J Radiat Oncol Biol Phys, 55(1): 51-63. [DOI:10.1016/S0360-3016(02)03866-X]

10. Shack L, Lu S, Weeks LA, et al. (2017) Determining the need and utilization of radiotherapy in cancers of the breast, cervix, lung, prostate and rectum: A population level study. Radiother Oncol, 122(1): 152-158. [DOI:10.1016/j.radonc.2016.12.006]

11. Foroudi F, Tyldesley S, Barbera L, et al. (2003) An evidence-based estimate of the appropriate radiotherapy utilization rate for colorectal cancer. Int J Radiat Oncol Biol Phys, 56(5): 1295-307. [DOI:10.1016/S0360-3016(03)00423-1]

12. Jairam V, Roberts KB, Yu JB (2013) Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008. Int J Radiat Oncol Biol Phys, 85(3): e151-5. [DOI:10.1016/j.ijrobp.2012.10.007]

13. Dong S and Yu S (2013) Current status of chemotherapy induced nausea and vomiting. Chinese J Evidence-based Medicine, 13(6): 687-691.

14. Ping P, Wu C, Gu K, et al. (2016) Analysis of the incidence and time trend of pediatric tumors in Shanghai. Chin J Epidemiol, 37(1): 106-110.

15. Tsuchida M, Ohara A, Manabe A, et al. Tokyo children's cancer study group (2010) long-term results of Tokyo children's cancer study group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia, 24(2): 383-96. [DOI:10.1038/leu.2009.260]

16. Zhang P, Li X, Wang Q (2017) Research progress on the risk factors of pediatric tumors. Chongqing Medical Journal, 30: 4288-4292.

17. Linabery AM and Ross JA (2008) Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer, 113: 2575-2596. [DOI:10.1002/cncr.23866]

18. Ljungman G, Jakobson A, Behrendtz M, et al. Swedish childhood solid tumor working group (VSTB). (2011) incidence and survival analyses in children with solid tumors diagnosed in Sweden between 1983 and 2007. Acta Paediatr, 100(5): 750-7. [DOI:10.1111/j.1651-2227.2010.02122.x]

19. Zhi Y, Gao L, Xu G, et al. (2006) Preliminary results of intensity-modulated radiotherapy for nasopharyngeal carcinoma. Chin J Radiation Oncology, 15(4): 237-243.

20. Allen AM, Pawlicki T, Dong L, et al. (2012) An evidence-based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol, 103(1): 8-11. [DOI:10.1016/j.radonc.2012.02.001]

21. Larsen MH, Larsen EH, Ruud E, et al. (2022) I have to do things differently now, but I make it work-young childhood cancer survivors' experiences of self-management in everyday living. J Cancer Surviv, 16(4): 728-740. [DOI:10.1007/s11764-021-01066-y]

22. Hocking MC, Walsh KS, Hardy KK, Conklin HM (2021) Addressing neurocognitive late effects in pediatric cancer survivors: Current approaches and future opportunities. J Clin Oncol, 39(16): 1824-1832. [DOI:10.1200/JCO.20.02327]

23. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Childhood Cancer Survivor Study (2003) Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer, 97(3): 663-73. [DOI:10.1002/cncr.11095]

24. Follin C and Erfurth EM (2016) Long-Term Effect of Cranial Radiotherapy on Pituitary-Hypothalamus Area in Childhood Acute Lymphoblastic Leukemia Survivors. Curr Treat Options Oncol, 17(9): 50. [DOI:10.1007/s11864-016-0426-0]

25. Hull MC, Morris CG, Pepine CJ, Mendenhall NP (2003) Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA, 290(21): 2831-7. [DOI:10.1001/jama.290.21.2831]

26. Kahn JM, Keegan TH, Tao L, et al. (2016) Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma. Cancer, 122(17): 2723-30. [DOI:10.1002/cncr.30089]

27. Wang G (2007) Radiotherapeutics of pediatric cancer. 2nd Edition. Shanghai: Shanghai Science Press 2007: 138.

28. Sterzing F, Hauswald H, Uhl M, et al. (2010) Spinal cord sparing reirradiation with helical tomotherapy. Cancer, 116(16): 3961-8. [DOI:10.1002/cncr.25187]

29. Sandlund JT and Hudson MM (2010) Hematology: Treatment strategies for pediatric Hodgkin lymphoma. Nat Rev Clin Oncol, 7(5): 243-4. [DOI:10.1038/nrclinonc.2010.48]

30. Wolden SL, Chen L, Kelly KM, et al. (2012) Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. J Clin Oncol, 30(26): 3174-80. [DOI:10.1200/JCO.2011.41.1819]

31. Dörffel W, Rühl U, Lüders H, et al. (2013) Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol, 31(12): 1562-8. [DOI:10.1200/JCO.2012.45.3266]

32. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al. (2007) Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer, 110(1): 179-85. [DOI:10.1002/cncr.22762]

33. Qiu B and Matthay KK (2022) Advancing therapy for neuroblastoma. Nat Rev Clin Oncol, 19(8): 515-533. [DOI:10.1038/s41571-022-00643-z]

34. Berlanga P, Cañete A, Castel V (2017) Advances in emerging drugs for the treatment of neuroblastoma. Expert Opin Emerg Drugs, 22(1): 63-75. [DOI:10.1080/14728214.2017.1294159]

35. Mandell LR, Wollner N, Fuks Z (1987) Is cranial radiation necessary for CNS prophylaxis in pediatric NHL? Int J Radiat Oncol Biol Phys, 13(3): 359-63. [DOI:10.1016/0360-3016(87)90009-5]

36. Cohn SL, Pearson AD, London WB, et al. INRG Task Force (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol, 27(2): 289-97. [DOI:10.1200/JCO.2008.16.6785]

37. DuBois SG, Chesler L, Groshen S, et al. (2012) Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approach to neuroblastoma therapy trial. Clin Cancer Res, 18(9): 2679-86. [DOI:10.1158/1078-0432.CCR-11-3201]

38. Wilson JS, Gains JE, Moroz V, et al. (2014) A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer, 50(4): 801-15. [DOI:10.1016/j.ejca.2013.11.016]

39. Abramson DH (2005) Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci, 46(8): 2683-91. [DOI:10.1167/iovs.04-1462]

40. Lu Y and Tong J (2016) The pathogenesis, diagnosis and treatment of retinoblastoma. Modern Cancer Medicine, 24(6): 1007-1014.

41. Hu X, Fang Y, Hui X, et al. (2016) Radiotherapy for diffuse brainstem glioma in children and young adults. Cochrane Database Syst Rev, 2016(6): CD010439. [DOI:10.1002/14651858.CD010439.pub2]

42. Hug EB, Muenter MW, Archambeau JO, et al. (2002) Conformal proton radiation therapy for pediatric low-grade astrocytomas. Strahlenther Onkol, 178(1): 10-7. [DOI:10.1007/s00066-002-0874-2]

43. Singh P, Singh D, Kumar B, et al. (2022) Profile and clinical outcome of children with wilms' tumor treated at a tertiary care centre, India. South Asian J Cancer, 11(3): 260-268. [DOI:10.1055/s-0042-1743414]

44. Metzger ML and Dome JS (2005) Current therapy for Wilms' tumor. Oncologist, 10(10): 815-26. [DOI:10.1634/theoncologist.10-10-815]

45. Pritchard-Jones K, Bergeron C, de Camargo B, et al. SIOP Renal Tumours Study Group. (2015) Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet, 386(9999): 1156-64. [DOI:10.1016/S0140-6736(14)62395-3]

46. Vujanić GM, Mifsud W, Chowdhury T, et al. Renal Tumor Special Interest Group of the Children's Cancer and Leukaemia Group (2022) Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020). Cancer, 128(8): 1666-1675. [DOI:10.1002/cncr.34107]

47. Missaoui N, Landolsi H, Jaidene L, et al. (2010) Pediatric rhabdomyosarcomas in Tunisia. Asian Pac J Cancer Prev, 11(5): 1325-7.

48. van Gaal JC, Roeffen MH, Flucke UE, et al. (2013) Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. Eur J Cancer, 49(16): 3462-70. [DOI:10.1016/j.ejca.2013.06.022]

49. Park M, Lim J, Lee JA, et al. (2021) Cancer incidence and survival among adolescents and young adults in Korea: An update for 2016. Cancer Res Treat, 53(1): 32-44. [DOI:10.4143/crt.2020.644]

50. Authors??? Rhabdomyosarcoma. (2019) Nat Rev Dis Primers, 5(1): 2. [DOI:10.1038/s41572-018-0057-9]

51. Bisogno G, De Salvo GL, Bergeron C, et al. European paediatric Soft tissue sarcoma Study Group (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol, 20(11): 1566-1575. [DOI:10.1016/S1470-2045(19)30617-5]